[Skip to Navigation]
January 1990

Ruptured Arteriovenous Malformation Complicating Thrombolytic Therapy With Tissue Plasminogen Activator

Author Affiliations

From the Department of Internal Medicine, New Rochelle (NY) Hospital Medical Center (Dr Proner), and the Department of Neurosurgery, Mount Sinai Medical Center, New York, NY (Drs Rosenblum and Rothman).

Arch Neurol. 1990;47(1):105-106. doi:10.1001/archneur.1990.00530010131032

• It is thought that the clot-specific activity of tissue plasminogen activator, used in the treatment of acute myocardial infarction, makes bleeding complications less common than does the use of either streptokinase or urokinase. The incidence of intracerebral hemorrhage complicating the use of tissue plasminogen activator has been estimated to be 0.68%. This is a report of the rupture of an intracranial arteriovenous malformation complicating the use of tissue plasminogen activator therapy. Theories for the mechanism of hemorrhage in this instance are presented, as are suggestions for future use of the enzyme.

Add or change institution